Rhumbline Advisers Takes Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 76,472 shares of the biopharmaceutical company’s stock, valued at approximately $136,000. Rhumbline Advisers owned 0.12% of Regulus Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of RGLS. Vanguard Group Inc. grew its holdings in shares of Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the period. CVI Holdings LLC purchased a new stake in Regulus Therapeutics during the first quarter worth approximately $4,050,000. Bank of New York Mellon Corp purchased a new stake in Regulus Therapeutics during the second quarter worth approximately $352,000. Opaleye Management Inc. acquired a new stake in shares of Regulus Therapeutics in the first quarter worth $490,000. Finally, RA Capital Management L.P. purchased a new position in shares of Regulus Therapeutics in the 1st quarter valued at $18,000,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Price Performance

Shares of RGLS opened at $1.61 on Monday. The company has a 50-day moving average of $1.63 and a two-hundred day moving average of $2.05. The stock has a market cap of $105.40 million, a price-to-earnings ratio of -1.10 and a beta of 1.63. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). Analysts anticipate that Regulus Therapeutics Inc. will post -0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RGLS shares. Oppenheimer reissued an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Canaccord Genuity Group raised their price objective on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, August 9th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.